Compare Centene Corp (CNC) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs FMC Corp — how do they compare? Centene Corp trades at $66.8 (market cap $33.93B), while FMC Corp trades at $10.75 (market cap $1.34B). The key difference: Centene Corp is far larger — about 25.3× FMC Corp's market cap, and FMC Corp pays a 2.99% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| CNC | FMC | |
|---|---|---|
Market Cap | $33.93B | $1.34B |
Sector | Health | Basic Materials |
52-Week High | $68.72 | $43.90 |
52-Week Low | $25.21 | $10.72 |
Enterprise Value | $26.56B | $5.49B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.
Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.
FMC Corporation (FMC) trades at $10.91 with no change in the latest session. The agricultural sciences company shows mixed signals with a bearish technical outlook but positive analyst sentiment (47.6% buy ratings). Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submissions for new herbicide technology. However, fundamental challenges persist with negative net income margin of -72.93% and declining revenue from $5.8B in 2022 to $3.47B in 2025.
The stock presents a turnaround opportunity with attractive valuation metrics (P/S 0.4x, P/B 0.75x) and significant upside to the $16 consensus price target. Key risks include continued revenue declines, negative cash flow from operations, and high debt levels. The company's strategic moves to reduce debt and advance new products could drive recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
